Rojas S.,Institute Dalta Tecnologia Prbb Fundacio Privada Iat |
Rojas S.,Autonomous University of Barcelona |
Gispert J.D.,Institute Dalta Tecnologia Prbb Fundacio Privada Iat |
Gispert J.D.,CIBER ISCIII |
And 14 more authors.
Journal of Nanoparticle Research | Year: 2015
Nanoparticles have been proposed for several biomedical applications due to their potential as drug carriers, diagnostic and therapeutic agents. However, only a few of them have been approved for their use in humans. In order to gauge the potential applicability of a specific type of nanoparticle, in vivo biodistribution studies to characterize their pharmacokinetic properties are essential. In this regard, mesoporous silica nanoparticles (30–130 nm) have been functionalized with amino groups in order to react with N-succinimidyl 4-[18F]fluorobenzoate and thus anchor the 18F positron emission isotope by using a novel and easy labelling strategy. In vivo biodistribution was characterized in mice after intravenous administration of radiolabelled nanoparticles by positron emission tomography. Our results indicated that radiolabelled mesoporous silica nanoparticles were excreted into bile and urine and accumulated mainly in the organs of the reticuloendothelial system and lungs. © 2015, Springer Science+Business Media Dordrecht.
Martin-Garcia E.,University Pompeu Fabra |
Burokas A.,University Pompeu Fabra |
Martin M.,University Pompeu Fabra |
Berrendero F.,University Pompeu Fabra |
And 6 more authors.
Journal of Neurochemistry | Year: 2010
The endocannabinoid system plays a crucial role in the pathophysiology of obesity. However, the clinical use of cannabinoid antagonists has been recently stopped because of its central side-effects. The aim of this study was to compare the effects of a chronic treatment with the CB1 cannabinoid antagonist rimonabant or the CB1 inverse agonist taranabant in diet-induced obese female rats to clarify the biological consequences of CB 1 blockade at central and peripheral levels. As expected, chronic treatment with rimonabant and taranabant reduced body weight and fat content. Interestingly, a decrease in the number of CB1 receptors and its functional activity was observed in all the brain areas investigated after chronic taranabant treatment in both lean and obese rats. In contrast, chronic treatment with rimonabant did not modify the density of CB1 cannabinoid receptor binding, and decreased its functional activity to a lower degree than taranabant. Six weeks after rimonabant and taranabant withdrawal, CB1 receptor density and activity recovered to basal levels. These results reveal differential adaptive changes in CB1 cannabinoid receptors after chronic treatment with rimonabant and taranabant that could be related to the central side-effects reported with the use of these cannabinoid antagonists. © 2010 International Society for Neurochemistry.